PBA protects livers from IRI by depressing local pro-inflammatory immune response. PBA was administered 12 h prior to the ischemia insult (10 mg/kg, i.p). Liver injury and immune response were evaluated at 2 h and 6 h of reperfusion by (a) measuring sALT levels, Suzuki's scores of liver tissue damage and liver histology (H&E staining); n=8/group. (b) qRT-PCR of liver inflammatory gene expression programs (IL-12p40, IL-10, TNF-α, CXCL10); n=3/group.